Ignelzi Troy A. 4

What Happened
Troy A. Ignelzi, Chief Financial Officer of Rapport Therapeutics (RAPP), received an award of 148,000 derivative shares (reported as a grant) on February 2, 2026. The reported acquisition price is $0.00, so the filing lists the immediate reported value as $0 based on that price. This was an equity award (not an open-market buy or sale).

Key Details

• Transaction date: 2026-02-02
• Filing date: 2026-02-04 (filed within the typical two-business-day Form 4 window)
• Transaction type/code: Grant/Award (A), derivative securities
• Shares/units granted: 148,000; reported acquisition price: $0.00
• Shares owned after transaction: not specified in the provided filing
• Footnote: The shares underlying this award vest in 48 equal monthly installments beginning January 1, 2026, subject to continued service (Footnote F1)
• No 10b5-1 plan, tax-withholding, cashless exercise, or sale reported in this filing

Context
This is a compensation/retention equity grant that vests monthly over four years. Such awards are common and reflect company compensation practices rather than an immediate market buy or sell by the insider. Because the grant is reported as a derivative award with a $0.00 acquisition price, consult company disclosures (proxy or equity plan) for details on whether these are options, restricted stock units, or another instrument.